FAP and colorectal adenoma: For over three decades the role of aspirin in reducing colorectal cancer risk has been explored in a number of settings; in particular, for high-risk patients with FAP (Waddell and Loughry, 1983; Giardiello et al, 1993), HNPCC (Burn et al, 2011), patients already treated for colorectal adenomas (Baron et al, 2003), and for colorectal carcinomas (Rothwell et al, 2012).